$ELTX News

Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine

Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results At ESMO Congress 2026; Multiple Pre-Specified Subgroup Analyses Favored Camupepimut, Including Patients With And Without Detectable Baseline ctDNA; Encouraging Disease-Free Survival Outcomes Were Observed In Both ctDNA-Negative And ctDNA-Positive Patients

Elicio Therapeutics Presents Data From Its Phase 2 AMPLIFY-7P Trial Of Camupepimut At European Society For Medical Oncology Congress 2026

Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026

B. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8

Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Target

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Elicio Therapeutics Q2 EPS $(0.43) Beats $(0.54) Estimate

Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering

Another Blow For ELTX? Elicio Raises Fresh Capital Weeks After Trial Disappointment

Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering

Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes

Elicio Therapeutics Added To Russell 2000, 3000 Indexes, Effective June 26

Ladenburg Thalmann Assumes Elicio Therapeutics at Buy, Announces Price Target of $12

Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer

Elicio Therapeutics Reports 100% Complete Responses In Three Metastatic Pancreatic Cancer Patients Following ELI-002 7P And Nivolumab Therapy

Jones Trading Downgrades Elicio Therapeutics to Hold

ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints